Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alnus incana subsp. rugosa pollen
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Percutaneous
01
Overview
Alnus incana subsp. rugosa pollen is an allergenic extract derived from the pollen of the speckled alder tree, a species native to North America. [2] It is a biologic product used for both the diagnosis of allergies (via skin testing) and for allergen immunotherapy to treat patients with confirmed allergies to this specific pollen. [11] The therapy works by administering controlled, gradually increasing doses of the allergen subcutaneously, which modulates the immune system over time to reduce allergic sensitivity and induce tolerance. [10, 11] The product is available as an injectable solution or suspension and is marketed by companies including ALK-Abello, Inc. and Center Laboratories. [3, 4] It is an FDA-registered product that requires careful dose titration based on individual patient sensitivity. [4, 15]
- Brand names
- CENTER-AL
- Other names
- speckled alder pollentag alder pollensmooth alder pollenAlnus rugosa pollen
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Alnus incana subsp. rugosa pollen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alnus incana subsp. rugosa pollen.